NRx Pharmaceuticals, Inc. has completed a Type C guidance meeting with the U.S. Food and Drug Administration regarding NRX-100, its preservative-free intravenous ketamine formulation for treating suicidal depression. The meeting, led by FDA Division of Psychiatry Products, Office of Neuroscience, and Center for Drug Evaluation and Research leaders, provided the company with a clear path to file a New Drug Application based on existing trial data and Real World Evidence from over 65,000 patients. This development is significant because it could provide a safer alternative to current ketamine preparations containing benzethonium chloride, a toxic preservative no longer recognized as safe in foods or drugs.
The company plans to seek approval for a broader indication serving patients with treatment-resistant depression in the context of suicidality, rather than only those with active suicidality. Approval could give NRx access to what it estimates to be a $2 billion ketamine market currently served by intranasal S-ketamine. Dr. Jonathan Javitt, founder, Chairman and CEO of NRx Pharmaceuticals, stated the company will use clinical trial data together with proposed Real World Data from Osmind, Inc. to apply for approval of what they describe as a lifesaving drug for Americans including Veterans and First Responders.
In addition to the New Drug Application, NRx has filed an Abbreviated New Drug Application with the FDA, anticipating a summer 2026 decision date. The company reports the current market for IV ketamine is worth $750 million for anesthesia use, which they aim to replace with their modern formulation. This regulatory progress coincides with expansion of NRx's clinical delivery network through its HOPE Therapeutics subsidiary, which combines neuroplastic drugs like ketamine with Transcranial Magnetic Stimulation, Hyperbaric Oxygen Therapy and psychotherapy.
NRx recently partnered with neurocare group AG to provide combined medication and brain stimulation therapies, with pilot programs showing high remission rates among first responders with PTSD and depression. The company has been acquiring clinics, including contracts to purchase 10 interventional psychiatry clinics in California and Florida, which should be immediately accretive to revenue and EBITDA according to the company. Wall Street firm D. Boral has given the stock a buy rating with a $34 price target, citing momentum from the HOPE unit and developments with NRX-100 and NRX-101.
NRX-101, the company's FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain, remains on track. This oral fixed-dose combination targets the NMDA receptor critical for memory function and new thought formation, potentially becoming the first medicine regimen specifically for severe bipolar depression in patients with suicidal ideation. The company estimates over 13 million Americans seriously consider suicide each year who could benefit from these treatments.
Financially, NRx strengthened its position by eliminating $5.4 million in balance sheet debt through a strategic equity conversion with Anson Funds LLC. in late December, becoming debt-free as it advances its NMDA platform therapies. By combining regulatory progress with clinical expansion and financial stability, NRx Pharmaceuticals is positioning itself to address critical unmet needs in treating suicidal depression, PTSD and other central nervous system disorders through both pharmaceutical development and integrated care delivery.
